Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Apatinib PK in Healthy Volunteers
NCT02836821Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in Neoplasm, sponsored by Hengrui. Primary endpoint: Area under the plasma concentration versus time curve. Started May 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT02836821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836821.